|
Jul 24
|
Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program
|
|
Jun 24
|
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin
|
|
Mar 24
|
Creative Medical Technology Holdings Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Dec 20
|
Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain
|
|
May 22
|
Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development
|